When “on hold” means compliance trouble
A hospital-led covered entity in Ohio spent the first quarter of 2026 watching its contract pharmacy stock of Eliquis dwindle to zero. Cardinal Health had placed the 340B replenishment order, but the manufacturer’s portal flagged it as “pending ESP validation.” Forty-eight hours later, it was “on hold for shipment review.” The wholesaler confirmed the delay was tied to incomplete 340B claim data submission through the 340B ESP system, something the entity believed it had already transmitted weeks earlier. By the time the shipment was released, HRSA auditors were on-site reviewing contract pharmacy reconciliation reports. The gap between dispensing and restocking had stretched 19 days.
This kind of gap now has tangible oversight consequences. HRSA’s 2026 audit teams are directly verifying manufacturer shipping pauses and checking the covered entity’s documentation of those pauses. When replenishment stalls, auditors expect proof that no covered 340B drugs were diverted or replaced through non-340B inventory. The issue runs deeper than paperwork. Each delay exposes weak points in inventory integrity, patient eligibility tracking, and ESP data accuracy.
HRSA’s 2026 posture: delayed shipments equal data risk
For years, HRSA’s contract pharmacy oversight centered on eligibility and duplicate discounts. The focus has shifted, to the integrity of data between platforms. Since January 2026, manufacturer dependence on centralized validation tools like 340B ESP has intensified. Pfizer, Johnson & Johnson, and AstraZeneca now use ESP data to decide whether to release 340B orders from contract pharmacy accounts. When ESP records and wholesaler submissions don’t match, shipments simply stop. And OPA auditors are now recording how long each delay lasts and whether replenishment accuracy holds up afterward.
Entities are finding that a three-day restocking delay can morph into a 30-day compliance headache when the validation chain breaks. Once a restock sits idle, automatic replenishment triggers can pile up several unmatched dispenses. HRSA reviewers now expect clear reconciliations showing that every 340B claim was transmitted, validated, and refilled with the correct NDC at the correct ceiling price. No gaps, no excuses.
Adam Fein’s spring 2026 Drug Channels analysis noted how Cigna’s 340B “workarounds” rely on tight restocking cycles to maintain margin visibility. When those cycles collapse, both financial and compliance visibility fade fast. The same logic applies here: a delay hides whether drugs were ever properly replenished under 340B or reverted to WAC stock. Missing that distinction is exactly the kind of “material deficiency in program integrity” HRSA now flags.
ESP validation breakdowns and manufacturer pause policies
Most restocking delays today happen not because pharmacies misuse ESP, but because they misinterpret the late-2025 validation rules. Manufacturers now reject claims without the exact dispensing date, NDC-11, and Medicaid billing flag, all of which anchor duplicate discount prevention. One digit missing, the system freezes the order. Some manufacturers, like Merck after its 2026 ARPA pricing updates, even require a secondary confirmation through a third-party before shipping resumes.
This is where the real danger creeps in. Pharmacy inventory teams sometimes override delays by ordering drugs at WAC to keep dispensing running. On paper, it looks fine, patients get their meds. But the audit trail now shows a non-340B purchase backing what should have been a 340B dispense. HRSA auditors this year have repeatedly called that “substitution without reconciliation.” It’s entirely avoidable if entities keep a synchronized log of restocking pauses that matches manufacturer delay notices line for line.
One FQHC in Texas did the opposite. It froze dispensing of all affected NDCs until shipment clearance, citing “operational pause due to manufacturer restriction.” HRSA approved that mitigation because the entity documented every delayed shipment, attached each ESP rejection timestamp, and proved no diversion occurred. That level of tracking isn’t overkill anymore, it’s the baseline.
A tightening economic vise
Restocking delays land hard in an already stressed financial environment. Shrinking margins, tighter rebates, and compressed spreads have left 340B administrators watching every penny. Drug Channels’ March 2026 analysis underscored it: lowered list prices and recalculated Medicaid best prices keep pulling 340B ceiling prices downward. Add a shipment pause, and a quarter’s cash flow can collapse almost overnight.
Manufacturers justify the pauses as protection against duplicate discounts and ineligible capture. In reality, the administrative weight falls on the safety-net side, teams juggling ESP uploads, split-billing audits, and multiple distributor portals. HRSA’s February 2026 audit template even carved out a section titled “Manufacturer Restriction Response.” Entities must show the start and end date of each hold, the stated cause, and evidence the ESP data was eventually accepted. It’s an era of paperwork proof, not trust.
For administrators, the best defense has two parts: preserve proof of every hold, even short ones, and tie each to a reconciliation showing zero diversion or double purchase. HRSA doesn’t penalize manufacturer-caused holds, but it does cite sloppy or missing documentation. The safest stance? Over-document. Log every pause, validate claims every day, check ESP acceptance weekly. Many programs now dedicate a compliance technician just for this. Look, that might sound obsessive, but losing 340B pricing eligibility over a missing validation file is worse.
By mid-2026, it’s obvious: shipment delays aren’t a nuisance anymore, they’re a compliance variable. HRSA sees how mismatched data feeds risk for diversion, duplicate discounts, or unsupported accumulations. The covered entities that treat every paused shipment as a compliance event, tracking, documenting, reconciling, will weather the next audit cycle. The rest are playing catch-up, one delayed order at a time.
